No. Abridge is private and has not filed to go public. There is no S-1 on file.
What is Abridge's valuation in 2026?
Abridge is valued at $5.7B as of 2025-Q2, set by its Series E ($300M, Jun 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Abridge filed an S-1?
No public S-1 is on file for Abridge.
Who are Abridge's investors?
Abridge's investors include Andreessen Horowitz, Lightspeed Venture Partners, Bessemer Venture Partners, Redpoint, Spark Capital, Kaiser Permanente Ventures and 7 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Abridge is an enterprise-grade AI platform that transforms clinical conversations into structured documentation and actionable insights. Founded by cardiologist Dr. Shiv Rao in 2018, the company uses generative AI and ambient listening to capture patient-clinician conversations and automatically generate clinical notes, reducing administrative burden and allowing clinicians to focus on patient care. The platform integrates with Epic EHR systems and supports 55 medical specialties across 28 languages, serving over 150 health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and UPMC.
Company Profile
CEO
Shiv Rao
Founded
2018
HQ
Pittsburgh, Pennsylvania
Employees
488
Total Raised
$1.0B
Est. Revenue
$100M (2025-Q2)
Growth
900% YoY ARR growth; deployed to 150+ enterprise health systems; tracking 50M+ medical conversations annually
Last Round
Series E — $300M (Jun 2025)
IPO Status
Private
Fundraising Status
Series E · $300M · 1y 2mo ago
PrivateTotal raised $1.0B
Secondary Market
Implied price / share
$182.57
Last round price / share
$158.48
vs last round
+15.2%
Open interest
6
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series E
$300M
Jun 2025
—
—
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
45
via ashby
Product-build share
73%
engineering, research, product, design
Trajectory
steady
heavy product build — 73% of open roles are product-building functions (engineering/research/product) — 11 of 45 open roles are engineering.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Machine Learning Scientist (All Levels)Senior Platform EngineerSenior Full Stack Engineer, Integrations VistA Senior Application Security EngineerSenior Data ScientistMachine Learning Infrastructure Engineer, Model Inference
Counted from Abridge's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Shiv RaoSandeep KonamFlorian Metze
Investors
Andreessen Horowitz · Lightspeed Venture Partners · Bessemer Venture Partners · Redpoint · Spark Capital · Kaiser Permanente Ventures · CVS Health Ventures · Khosla Ventures · California Health Care Foundation · NVIDIA NVentures · WndrCo · Emerson Collective · UPMC
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.